Recordati S.p.A

Recordati S.p.A was founded in 1926 by Giovanni Recordati, a pharmacist and entrepreneur who started his own laboratory in Milan. The company's headquarters are located in Milan, Italy, but it has operations in more than 40 countries across Europe, North America, Asia, Africa, and Latin America.

Recordati S.p.A produces and markets innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas such as cardiovascular, urological, gastroenterological, metabolic, and rare diseases. The company's product portfolio includes original drugs such as Zanidip®, Zanipress®, Lercanidipine Generics, Urorec®, Procto-Glyvenol®, Silodyx®, Reagila®, Isturisa®, and many others. The company also has a dedicated business unit for rare diseases, which offers treatments for conditions such as Cushing's syndrome, acromegaly, hyperammonemia, hereditary angioedema, and others.

Recordati S.p.A has a strong commitment to research and development of new specialties, with a focus on rare diseases. In 2022, the company invested € 156.5 million in R&D, representing 8.4% of its revenue. The company's market capitalization as of May 13th, 2023 was € 9.8 billion, making it one of the largest pharmaceutical companies in Italy and Europe.

Recordati S.p.A's vision is to be a global leader in providing high-quality medicines that improve the health and well-being of people around the world. The company has received several awards and recognitions for its performance, innovation, and social responsibility. For example, in 2022 it was ranked among the top 10 best employers in Italy by Forbes magazine.

Foundation: 1926

Headquarters: Milan, Italy

Website: https://www.recordati.com/en/